INTELLIGENT BIO SOLUTIONS INC. current report, 13 March 2023

Business Context and Reporting Period

Company: Intelligent Bio Solutions Inc. (INBS)
Filing Type: Form 8-K (Current Report)
Date of Report: March 13, 2023
Reporting Period: Single event date (March 13, 2023)
Business Context: The Company is an emerging growth company focused on drug testing technology, specifically its Intelligent Fingerprinting System which analyzes sweat to screen for recent drug use.

Key Financial Metrics

This filing is a current report regarding a specific corporate event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.

Material Changes

Strategic Partnership: On March 13, 2023, the Company announced the selection of Human and Supplement Testing Australia ("HASTA") as its preferred drug testing specialist in Australia. This partnership is intended to facilitate lab-based confirmation testing for the Company's Intelligent Fingerprinting System in the Australian market.

Guidance, Outlook, and Risks

Management Commentary: The filing references a press release (Exhibit 99.1) detailing the partnership with HASTA. The disclosure is qualified in its entirety by the full text of that press release.
Risks and Contingencies: No specific financial risks or contingencies are detailed in this 8-K text beyond the standard regulatory disclaimer that the information is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Guidance: No forward-looking financial guidance is provided in this document.

Investor Verification Checklist

  • Verify the full text of the Press Release (Exhibit 99.1) for specific terms of the agreement with HASTA.
  • Confirm the operational status and regulatory approval requirements for the Intelligent Fingerprinting System in Australia.
  • Review subsequent filings for any financial impact or revenue recognition related to this new partnership.
  • Check the Company's status as an emerging growth company for potential differences in financial reporting standards.